Novo Nordisk’s Awiqli Receives the CHMP’s Positive Opinion for the Treatment of Diabetes
Shots:
-
Novo Nordisk’s Awiqli (QW basal insulin icodec) has received CHMP’s positive opinion and recommending it for the final approval which is anticipated in next ~67days/ ~2mos
-
The opinion was supported by the six P-IIIa (ONWARDS) study assessing the safety & efficacy of Awiqli in type 1 & type 2 diabetes adults (n= >4,000) incl. Real-world analysis
-
The study showed superior blood sugar reduction (by HbA1c) & Time in Range (time spent in RBS range) among T2D patients. Awiqli reduced HbA1c, but had a higher hypoglycemia rate
Ref: Novo Nordisk | Image: Novo Nordisk
Related News:- Novo Nordisk Reports the Acquisition of Cardior Pharmaceuticals for ~$1.11B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
